Neurology Medical News about diabetic peripheral neuropathic pain; ABT-594

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain
Pain, 07/28/09

Rowbotham MC et al. – ABT–594 is a neuronal nicotinic acetylcholine receptor (NNR) agonist that exhibits potent analgesic activity in preclinical models of acute, chronic, and neuropathic pain...The proportion of patients achieving at least a 50% improvement in the average diary–based PRS was greater in all three ABT–594 treatment groups. However, adverse event (AE) dropout rates were significantly higher in all three ABT–594 treatment groups (28% for 150 microg BID, 46% for 225 microgg BID, and 66% for 300 microgg BID) than for the placebo group (9%). Consistent with the expected side–effect profile of NNR agonists, the most frequently reported AEs were nausea, dizziness, vomiting, abnormal dreams, and asthenia. This study establishes proof of concept for NNR agonists as a new class of compounds for treating neuropathic pain.

<< Previous
Modified orbitozygomatic craniotomy for large medial sphenoid...

Next >>
Secondary Stroke Prevention Strategies for the Oldest Patients:...